Article

RLE with new accommodative IOL offers good distance, near vision

Six-month results show 88% achieving 20/40 for distance, 70% achieving J3 or better

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
Related Content
Q&A: Yasha S. Modi, MD, on retinal nonperfusion in diabetic retinopathy
May 20th 2025

Q&A: Yasha S. Modi, MD, on retinal nonperfusion in diabetic retinopathy

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Kriya Therapeutics announces preclinical data for KRIYA-825, gene therapy injection for the treatment of GA
May 20th 2025

Kriya Therapeutics announces preclinical data for KRIYA-825, gene therapy injection for the treatment of GA

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Ashvattha reports positive phase 2 data for migaldendranib in retinal diseases
May 19th 2025

Ashvattha reports positive phase 2 data for migaldendranib in retinal diseases

Therini Bio raises $39 million in a Series A extension financing
May 19th 2025

Therini Bio raises $39 million in a Series A extension financing

© 2025 MJH Life Sciences

All rights reserved.